Insider Selling: Palvella Therapeutics (NASDAQ:PVLA) Director Sells $49,141.00 in Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Director Christopher Kiritsy sold 313 shares of Palvella Therapeutics stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $157.00, for a total value of $49,141.00. Following the transaction, the director directly owned 250 shares in the company, valued at approximately $39,250. This trade represents a 55.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Palvella Therapeutics Stock Performance

Shares of NASDAQ PVLA opened at $157.24 on Monday. The stock has a market cap of $2.27 billion, a P/E ratio of -32.55 and a beta of -0.25. Palvella Therapeutics, Inc. has a twelve month low of $52.36 and a twelve month high of $161.38. The stock has a 50 day moving average of $148.35 and a two-hundred day moving average of $129.80.

Palvella Therapeutics (NASDAQ:PVLA) last announced its earnings results on Tuesday, August 4th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). As a group, research analysts predict that Palvella Therapeutics, Inc. will post -6.36 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on PVLA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Monday, June 29th. Stephens reaffirmed an “overweight” rating and set a $220.00 price objective on shares of Palvella Therapeutics in a research report on Thursday, May 21st. Truist Financial set a $207.00 target price on Palvella Therapeutics in a research note on Wednesday, August 5th. Canaccord Genuity Group set a $232.00 price target on Palvella Therapeutics in a research note on Wednesday, August 5th. Finally, Chardan Capital upgraded shares of Palvella Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $209.14.

Hedge Funds Weigh In On Palvella Therapeutics

Large investors have recently modified their holdings of the business. California State Teachers Retirement System boosted its stake in shares of Palvella Therapeutics by 24,639.3% in the second quarter. California State Teachers Retirement System now owns 1,705,777 shares of the company’s stock valued at $260,677,000 after buying an additional 1,698,882 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of Palvella Therapeutics during the 2nd quarter worth $140,343,000. Summit Partners Public Asset Management LLC grew its stake in shares of Palvella Therapeutics by 1,016.0% during the 4th quarter. Summit Partners Public Asset Management LLC now owns 389,420 shares of the company’s stock worth $40,761,000 after purchasing an additional 354,525 shares during the period. Vanguard Group Inc. increased its holdings in shares of Palvella Therapeutics by 202.0% in the 3rd quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock valued at $31,010,000 after purchasing an additional 330,847 shares in the last quarter. Finally, State Street Corp lifted its stake in shares of Palvella Therapeutics by 206.3% in the fourth quarter. State Street Corp now owns 420,462 shares of the company’s stock valued at $44,010,000 after purchasing an additional 283,211 shares during the period. 40.11% of the stock is owned by hedge funds and other institutional investors.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.